First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced CancersBranimir I. Šikić, Sukhmani K. Padda, George A. Fisher et al.|Journal of Clinical Oncology|2019Cited by 590
Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcomaBadreddin Edris, Matt van de Rijn, Kipp Weiskopf et al.|Proceedings of the National Academy of Sciences|2012Cited by 256
Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growthBadreddin Edris, Matt van de Rijn, Kipp Weiskopf et al.|Proceedings of the National Academy of Sciences|2013Cited by 55
A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.George A. Fisher, Amita Patnaik, Nehal J. Lakhani et al.|Journal of Clinical Oncology|2020Cited by 53
A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.Nehal J. Lakhani, Kathleen N. Moore, Amita Patnaik et al.|Journal of Clinical Oncology|2020Cited by 37